Community-based care vs. centralised hospitalisation for MDRTB patients, KwaZulu-Natal, South Africa

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 2, 2015, Pages 163-171

  Loveday, M ^a   Wallengren, K ^b   Brust, J ^c   Roberts, J ^d   Voce, A ^e   Margot, B ^f   Ngozo, J ^f   Master, I ^g   Cassell, G ^h   Padayatchi, N ⁱ  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b TB and HIV Investigative Network (Think)   (South Africa)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f KwaZulu Natal Department of Health   (South Africa)

^g King DinuZulu Hospital   (South Africa)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

HIV; Models of care; Outcomes

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMMUNITY CARE; DIRECTLY OBSERVED THERAPY; DRUG TREATMENT FAILURE; FEMALE; HEALTH CARE ACCESS; HOME CARE; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT TRANSPORT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH AFRICA; SURVIVAL RATE; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEALTH CARE DELIVERY; HIV INFECTIONS; HOSPITALIZATION; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; THEORETICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COHORT STUDIES; COMMUNITY HEALTH SERVICES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MODELS, THEORETICAL; PROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84937138009     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0369     Document Type: Article

References (28)

1. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
2. Gandhi N, Shah S, Andrews J, et al. HIV co-infection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. AmJ Respir Crit Care Med 2010; 181: 80-86.
3. Wallengren K, Scano F, Margot B, et al. Resistance to TB drugs in KwaZulu-Natal: causes and prospects for control. Ithaca, NY, USA: Cornell University Library, 2011. http://arxiv.org/abs/1107.1800. Accessed October 2014.
4. Zager E, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis 2008; 8: 10.
5. Brust J, Gandhi N, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrugresistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413-419.
6. Wallengren K, Scano F, Margot B, et al. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerg Infect Dis 2011; 17: 1913-1916.
7. Oyieng'o D, Park P, Gardner A, et al. Community-based treatment of multidrug-resistant tuberculosis: early experience and results fromWestern Kenya. Public Health Action 2012; 2: 38-42.
8. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multi-drug resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
9. Kim H, Hong Y, Kim S, LewW, Lee E. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
10. Van Deun A, Hamid Salim M, Kumar Das A, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
11. Keshavjee S, Gelmanova I, Pasechnikov A, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008; 1136: 1-11.
12. Satti H, McLaughlin M, Hedt-Gauthier B, et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLOS ONE 2012; 7: e46943.
13. South African Department of Health. Management of drugresistant tuberculosis: policy guidelines. Pretoria, South Africa: DoH, 2008.
14. South African Department of Health. Clinical guidelines for the management of HIV and AIDS in adults and adolescents. Pretoria, South Africa: Department of Health, 2010. http://www.doh.gov.za/docs/facts-f.html Accessed October 2014.
15. Loveday M, Wallengren K, Voce A, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16: 209-215.
16. Brust J, Shah N, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
17. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
18. Laserson K, Thorpe L, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
19. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB) indicators: a minimum set of indicators for the programmatic management of MDR-TB in national tuberculosis control programmes. WHO/HTM/TB/2010.11. Geneva, Switzerland: WHO, 2010.
20. Falzon D, Jaramillo E, Schunemann H, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Eur Respir J 2011; 38: 516-528.
21. Toczek A, Cox H, du Cros P, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
22. Cox H, Hughes J, Daniels J, et al. Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa Int J Tuberc Lung Dis 2014; 18: 441-448.
23. Loveday M, Padayatchi N, Wallengren K, et al. Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: implications for TB programmes. PLOS ONE 2014; 9: e94016.
24. Atun R. Health systems, systems thinking and innovation. Health Policy Plan 2012; 27 (Suppl 4): iv4-iv8.
25. Tkatchenko-Schmidt E, Atun R, Wall M, Tobi P, Schmidt J, Renton A. Why do health systems matter? Exploring links between health systems and HIV response: a case study from Russia. Health Policy Plan 2010; 25: 283-291.
26. Brinkhof M, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLOS ONE 2009; 4: e5790.
27. Bassett I, Chetty S, Wang B, et al. Loss to Follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Acquir Immune Defic Syndr 2012; 59: 25-30.
28. Abdool Karim S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.